Alkermes Toekomstige groei
Future criteriumcontroles 3/6
Alkermes zal naar verwachting groeien in winst en omzet met respectievelijk 30.4% en 9.9% per jaar. De winst per aandeel zal naar verwachting groeien met 28.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.7% zijn.
Belangrijke informatie
30.4%
Groei van de winst
28.78%
Groei van de winst per aandeel
| Biotechs winstgroei | 23.1% |
| Inkomstengroei | 9.9% |
| Toekomstig rendement op eigen vermogen | 11.66% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 29 Apr 2026 |
Recente toekomstige groei-updates
Recent updates
ALKS: Sleep Franchise And Orexin Program Will Shape Future Upside Potential
Narrative Update: Alkermes Analyst Price Target Shift The updated analyst price target for Alkermes moves modestly higher by about $0.53, as analysts factor in revised assumptions around revenue growth, profit margins, and a higher future P/E, tied in part to the evolving sleep and narcolepsy franchise following recent research updates. Analyst Commentary Recent research on Alkermes reflects a mix of optimism around the sleep and narcolepsy portfolio and caution on execution, pricing assumptions, and the performance of legacy products.ALKS: Sleep Franchise And Orexin Pipeline Will Drive Future Upside
Analysts made a small upward adjustment in the price target for Alkermes to about $43.71, supported by refreshed models around the company's emerging sleep and narcolepsy franchise, recent M&A activity in the biotech space, and updated views on future P/E multiples and profitability. Analyst Commentary Recent Street research on Alkermes circles around how the emerging sleep and narcolepsy franchise, the Avadel acquisition, and updated pricing assumptions could feed into growth expectations, while also flagging execution and valuation risks.
ALKS: Sleep Franchise And Orexin Breakthrough Will Drive Future Upside Potential
Narrative Update The updated analyst price target for Alkermes moves to $31.30 from $30.00, as analysts factor in revised revenue growth assumptions tied to the expanding sleep and narcolepsy franchise and the completed Avadel acquisition, along with adjusted views on profit margins and future P/E. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with analysts weighing the potential of the sleep and narcolepsy franchise against execution and valuation questions.ALKS: Emerging Sleep Franchise And Orexin Program Will Drive Future Upside
Narrative Update on Alkermes The updated analyst price target for Alkermes edges down from $43.75 to about $43.65, as analysts balance slightly higher modeled revenue growth with lower profit margin assumptions and a higher future P/E tied to the growing sleep and narcolepsy franchise, including Lumryz and the orexin program. Analyst Commentary Recent Street research on Alkermes presents a mixed picture, with some analysts leaning constructive on the emerging sleep and narcolepsy portfolio and others more restrained on valuation and execution risk.ALKS: Improved CVR Offer Terms Will Support Future Sleep Disorder Leadership
Analysts have slightly lowered their price target on Alkermes to $43.75 from $43.81, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E after reviewing the company's revised offer terms highlighted in recent Street research. Analyst Commentary Recent Street research around Alkermes is centered on the revised offer terms, especially the contingent value right, or CVR, structure that sits alongside the upfront consideration.ALKS: Avadel Bid And Orexin Breakthrough Status Will Support Future Sleep Leadership
Analysts kept their Alkermes fair value estimate steady at about $43.81 per share while nudging up projected revenue growth and future P/E assumptions and trimming profit margin expectations, reflecting mixed reactions to the latest narcolepsy data and the evolving Avadel bid. Analyst Commentary Street research around Alkermes focuses on the mixed narcolepsy data, the competitive orexin pipeline, and the evolving Avadel bid, with investors weighing both upside optionality and execution risks.
ALKS: Avadel Sleep Deal And Orexin Breakthrough Designation Will Drive Upside
Analysts have trimmed their Alkermes price target by a small amount to reflect a slightly higher discount rate and somewhat lower expected profit margin, while still factoring in stronger modeled revenue growth and updated views on the Avadel acquisition and alixorexton sleep pipeline data. Analyst Commentary Bullish analysts are generally framing the recent updates around Alkermes as a mixed but constructive setup, with the Avadel acquisition and alixorexton data keeping the stock firmly on institutional radar.Alkermes: Avadel Deal And Vibrance-2 Unlock Upside
Jan 09ALKS: Sleep Franchise Acquisition Will Drive Future Orexin Class Leadership
Analysts have trimmed their Alkermes fair value estimate by about $0.06 per share to $43.81 as they weigh mixed alixorexton data against generally positive views on the Avadel acquisition and Alkermes' role in the emerging orexin class. Analyst Commentary Street research around Alkermes and its sleep portfolio is split between enthusiasm for the Avadel acquisition and orexin opportunity, and caution around alixorexton data quality and competitive pressures.ALKS: Avadel Deal And Sleep Franchise Are Poised To Drive Upside
The analyst price target for Alkermes has been raised by about $4 to approximately $57 per share, as analysts factor in stronger expected revenue growth and profit margins supported by the strategic Avadel acquisition and resilient alixorexton sleep-disorder franchise prospects. Analyst Commentary Bullish analysts emphasize that the Avadel transaction, combined with a clearer outlook for alixorexton in narcolepsy and hypersomnia, materially improves Alkermes' growth, margin, and capital allocation story.ALKS: Sleep Medicine Acquisition Will Drive Future Orexin Opportunity Upside
Analysts modestly lift their price target on Alkermes, reflecting confidence that the strategically priced Avadel acquisition, solid narcolepsy data and an underappreciated orexin class opportunity can drive upside, despite only incremental changes to long term growth and profitability assumptions. Analyst Commentary Street views on Alkermes remain mixed, with a generally constructive stance on long term positioning in sleep medicine and orexin agonists, tempered by questions around differentiation, safety profile and competitive intensity.ALKS: Sleep Medicine Acquisition Will Drive Momentum After Narcolepsy Study Results
Analysts have slightly reduced their price target for Alkermes to $43.88 from $44, reflecting tempered revenue growth assumptions and competitive data from recent narcolepsy studies. Analyst Commentary Analyst sentiment regarding Alkermes remains divided following the latest developments in its narcolepsy franchise and pending acquisition of Avadel Pharmaceuticals.ALKS: Clinical Progress In Narcolepsy Will Drive Share Momentum This Fall
Analysts have raised their fair value estimate for Alkermes from $42.53 to $44.00 per share. They cite stronger revenue growth forecasts and recent clinical and strategic updates, which improve the company's near- and mid-term outlook.Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31
Analyst Commentary Highlights Growth Prospects and Risks Following Alkermes Acquisition and Updated Valuation
Alkermes' analyst price target was raised approximately $0.95 to $42.53 per share, as analysts point to improved profit margin outlook and the anticipated benefits from its Avadel Pharmaceuticals acquisition. These factors are expected to support both near- and mid-term growth.Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 48% Undervaluation?
May 31Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Feb 25Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Nov 24
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Alkermes: Fairly Valued After Post-Earnings Bump
Jul 28The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 2,064 | 259 | 577 | 410 | 11 |
| 12/31/2027 | 1,876 | 134 | 501 | 306 | 15 |
| 12/31/2026 | 1,796 | -109 | 346 | -7 | 17 |
| 12/31/2025 | 1,476 | 242 | 480 | 521 | N/A |
| 9/30/2025 | 1,521 | 338 | 491 | 541 | N/A |
| 6/30/2025 | 1,505 | 348 | 480 | 521 | N/A |
| 3/31/2025 | 1,514 | 356 | 482 | 517 | N/A |
| 12/31/2024 | 1,558 | 372 | 406 | 439 | N/A |
| 9/30/2024 | 1,505 | 387 | 315 | 356 | N/A |
| 6/30/2024 | 1,508 | 386 | 327 | 374 | N/A |
| 3/31/2024 | 1,726 | 570 | 394 | 444 | N/A |
| 12/31/2023 | 1,663 | 519 | 353 | 401 | N/A |
| 9/30/2023 | 1,591 | 455 | 254 | 295 | N/A |
| 6/30/2023 | 1,462 | 300 | 159 | 196 | N/A |
| 3/31/2023 | 1,121 | -9 | -59 | -22 | N/A |
| 12/31/2022 | 1,112 | -33 | -17 | 21 | N/A |
| 9/30/2022 | 1,132 | -129 | 14 | 51 | N/A |
| 6/30/2022 | 1,173 | -94 | 102 | 133 | N/A |
| 3/31/2022 | 1,201 | -62 | 140 | 169 | N/A |
| 12/31/2021 | 1,174 | 76 | 73 | 102 | N/A |
| 9/30/2021 | 1,129 | -92 | 112 | 138 | N/A |
| 6/30/2021 | 1,100 | -63 | 88 | 115 | N/A |
| 3/31/2021 | 1,044 | -95 | 48 | 78 | N/A |
| 12/31/2020 | 1,039 | -111 | 41 | 83 | N/A |
| 9/30/2020 | 1,171 | -74 | -11 | 58 | N/A |
| 6/30/2020 | 1,162 | -126 | -53 | 28 | N/A |
| 3/31/2020 | 1,194 | -139 | -78 | 10 | N/A |
| 12/31/2019 | 1,171 | -197 | -19 | 72 | N/A |
| 9/30/2019 | 1,074 | -201 | N/A | 91 | N/A |
| 6/30/2019 | 1,067 | -183 | N/A | 93 | N/A |
| 3/31/2019 | 1,092 | -173 | N/A | 148 | N/A |
| 12/31/2018 | 1,094 | -139 | N/A | 99 | N/A |
| 9/30/2018 | 1,054 | -139 | N/A | 75 | N/A |
| 6/30/2018 | 1,023 | -141 | N/A | 61 | N/A |
| 3/31/2018 | 937 | -152 | N/A | 6 | N/A |
| 12/31/2017 | 903 | -158 | N/A | 19 | N/A |
| 9/30/2017 | 842 | -169 | N/A | -9 | N/A |
| 6/30/2017 | 804 | -196 | N/A | -14 | N/A |
| 3/31/2017 | 781 | -200 | N/A | -20 | N/A |
| 12/31/2016 | 746 | -208 | N/A | -64 | N/A |
| 9/30/2016 | 695 | -257 | N/A | -69 | N/A |
| 6/30/2016 | 668 | -275 | N/A | -113 | N/A |
| 3/31/2016 | 624 | -274 | N/A | -100 | N/A |
| 12/31/2015 | 628 | -227 | N/A | -40 | N/A |
| 9/30/2015 | 640 | -127 | N/A | -29 | N/A |
| 6/30/2015 | 648 | -86 | N/A | -7 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei ALKS ( 30.4% per jaar) ligt boven de spaarquote ( 3.4% ).
Winst versus markt: De winst van ALKS ( 30.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.8% per jaar).
Hoge groeiwinsten: De winst van ALKS zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van ALKS ( 9.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.1% per jaar).
Hoge groei-inkomsten: De omzet van ALKS ( 9.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ALKS zal naar verwachting over 3 jaar laag zijn ( 11.7 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/01 05:04 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Alkermes plc wordt gevolgd door 34 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |